Rallybio Corp. (RLYB) intrinsic value & 10-year financials
Rallybio Corp. (RLYB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 43.0% a year to $858.0K, with an average return on invested capital of -3483.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.28
- Market cap
- $91.6M
- Revenue (FY2025)
- $858.0K
- Revenue growth (7-yr CAGR)
- 43.0%
- ROIC (10-yr avg)
- -3483.3%
- Free cash flow (FY2025)
- —
RLYB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $858.0K | -$9.0M | -$1.59 | — | -3853.6% | -88.9% |
| FY2024 | $600.0K | -$57.8M | -$1.33 | — | -10082.7% | -93.3% |
| FY2023 | — | -$74.6M | -$1.84 | -$60.3M | — | -81.1% |
| FY2022 | — | -$66.7M | -$2.09 | -$57.3M | — | -120.1% |
| FY2021 | — | -$47.0M | -$1.84 | -$45.9M | — | -17032.8% |
| FY2020 | — | -$26.4M | — | -$22.2M | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Rallybio Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Rallybio Corp has historically struggled to out-earn its cost of capital, averaging just -110.8% ROIC.
Rallybio Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Rallybio Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-52.81 per share.